Evidence map›Paper›PMID 39690183›Full record

ArticleLeukemia2025

T-cell diversity and exclusion of blood-derived T-cells in the tumor microenvironment of classical Hodgkin Lymphoma.

Nicole Seifert, Sarah Reinke, Johanna Grund, Berit Müller-Meinhard, Julia Richter, Thorsten Heilmann, Hans Schlößer, Michaela Kotrova, Monika Brüggemann, Peter Borchmann and 3 more

Abstract read
In one paragraph

Article in Leukemia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Nicole Seifert *Department of Medical Bioinformatics, University Medical Center Göttingen, Göttingen, Germany.ORCID 0000-0002-2191-523X
Sarah Reinke *Department of Pathology, Hematopathology Section, University Hospital Schleswig-Holstein Campus, Kiel, Germany.ORCID 0000-0001-9729-4030
Johanna GrundDepartment of Pathology, Hematopathology Section, University Hospital Schleswig-Holstein Campus, Kiel, Germany.
Berit Müller-MeinhardDepartment of Pathology, Hematopathology Section, University Hospital Schleswig-Holstein Campus, Kiel, Germany.
Julia RichterDepartment of Pathology, Hematopathology Section, University Hospital Schleswig-Holstein Campus, Kiel, Germany.ORCID 0000-0002-9543-4084
Thorsten HeilmannFranziskus-Hospital Harderberg, Osnabrück, Germany.
Hans SchlößerCenter of Molecular Medicine, Cologne Translational Immunology, University of Cologne, Cologne, Germany.
Michaela KotrovaDepartment of Hematology and Oncology, University Hospital Schleswig-Holstein Campus, Kiel, Germany.
Monika BrüggemannDepartment of Hematology and Oncology, University Hospital Schleswig-Holstein Campus, Kiel, Germany.
Peter BorchmannDepartment I of Internal Medicine, Centre for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
Paul J BröckelmannDepartment I of Internal Medicine, Centre for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.ORCID 0000-0001-9662-9900
Michael AltenbuchingerDepartment of Medical Bioinformatics, University Medical Center Göttingen, Göttingen, Germany.
Wolfram KlapperDepartment of Pathology, Hematopathology Section, University Hospital Schleswig-Holstein Campus, Kiel, Germany. wklapper@path.uni-kiel.de.ORCID 0000-0001-7208-4117

Funding

Deutsche Krebshilfe (German Cancer Aid) 70112502Else Kröner-Fresenius-Stiftung (Else Kroner-Fresenius Foundation) Excellence Stipend
6 · The paper itself

Abstract

The Tumor Microenvironment (TME) in classical Hodgkin Lymphoma (HL) contains abundant immune cells and only few neoplastic Hodgkin and Reed-Sternberg cells (HRSC). We analyzed the T-cell receptor (TCR) repertoire to detect T-cell expansion in the TME and blood. In contrast to solid cancer tissue, T-cells in the TME of HL are highly polyclonal at first diagnosis and show only minor clonal expansion during anti-PD1 immune checkpoint blockade (ICB). At relapse and during ICB, pre-amplified T-cell populations increase in the TME of solid cancers but to a much lesser extent in HL. In contrast, T-cell populations in the peripheral blood of HL patients display higher clonality than healthy controls reaching clonality levels comparable to solid cancer. However, pre-amplified blood T-cells in HL patients show only minor additional clonal expansion during ICB. Moreover, blood-derived T-cells do not repopulate the TME of HL to the same extent as observed in solid cancers. Thus, the T-cell repertoire in the TME of HL appears unique by a relatively low clonal T-cell content and the exclusion of clonally expanded T-cells from the peripheral blood. Exclusion of clonally expanded tumor-specific T-cells from the TME may present a novel mechanism of immune evasion in HL.

Indexed as

Hodgkin DiseaseT-LymphocytesTumor MicroenvironmentAdultAgedFemaleHumansMaleMiddle AgedReceptors, Antigen, T-CellReed-Sternberg CellsReceptors, Antigen, T-Cell

Identifiers

PMID39690183
PMCPMC11879864

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.